Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Multicenter, Open Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

Next Previous
Trial Profile

A Phase 1b, Multicenter, Open Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tegoprubart (Primary) ; Antithymocyte globulin; Mycophenolate mofetil; Steroids
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Eledon Pharmaceuticals

Most Recent Events

  • 23 Jan 2026 Results presented in the Eledon Pharmaceuticals media release.
  • 08 Jan 2026 According to an Eledon Pharmaceuticals media release, long-term data from the Phase 1 and Phase 2 BESTOW studies evaluating tegoprubart in kidney transplantation is anticipated to be reported in 2026.
  • 08 Jan 2026 According to an Eledon Pharmaceuticals media release, the company expects to present a poster sharing 24-month data from eight patients in Phase 1 extension study evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons (ASTS) Winter Symposium on Friday, January 23, 2026 in Phoenix, AZ.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top